BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10213217)

  • 1. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.
    Scorilas A; Yotis J; Pateras C; Trangas T; Talieri M
    Clin Cancer Res; 1999 Apr; 5(4):815-21. PubMed ID: 10213217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
    Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
    Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
    Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
    Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
    Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of c-erbB2 expression in breast cancer.
    Tsutsui S; Ohno S; Murakami S; Hachitanda Y; Oda S
    J Surg Oncol; 2002 Apr; 79(4):216-23. PubMed ID: 11920778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.
    Scorilas A; Talieri M; Ardavanis A; Courtis N; Dimitriadis E; Yotis J; Tsiapalis CM; Trangas T
    Cancer Res; 2000 Oct; 60(19):5427-33. PubMed ID: 11034084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
    Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
    Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer.
    Kato T; Kimura T; Miyakawa R; Fujii A; Yamamoto K; Kameoka S; Nishikawa T; Kasajima T
    Br J Cancer; 2000 Jan; 82(2):404-11. PubMed ID: 10646896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
    Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence.
    Ardavanis A; Scorilas A; Loukeri A; Gerakini F; Pissakas G; Missitzis I; Apostolikas N; Yiotis I
    Anticancer Res; 1998; 18(4B):2885-90. PubMed ID: 9713481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
    Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
    Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of c-erbB2 protein and its relation to prognosis in 284 primary breast cancer patients].
    Yang LF; Song ST; Li XB; Jiang ZF; Liu XQ; Ma WN; Jiao XP; Guo SQ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):294-7. PubMed ID: 16875632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.
    Liu S; Edgerton SM; Moore DH; Thor AD
    Clin Cancer Res; 2001 Jun; 7(6):1716-23. PubMed ID: 11410511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.